WallStSmart

IRIDEX Corporation (IRIX)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 69062% more annual revenue ($36.36B vs $52.58M). MDT leads profitability with a 13.2% profit margin vs -6.2%. IRIX appears more attractively valued with a PEG of 0.94. MDT earns a higher WallStSmart Score of 62/100 (C+).

IRIX

Avoid

32

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 7.7Quality: 5.0
Piotroski: 4/9Altman Z: -2.51

MDT

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IRIXUndervalued (+75.3%)

Margin of Safety

+75.3%

Fair Value

$5.79

Current Price

$0.86

$4.93 discount

UndervaluedFair: $5.79Overvalued
MDTUndervalued (+10.6%)

Margin of Safety

+10.6%

Fair Value

$91.75

Current Price

$86.88

$4.87 discount

UndervaluedFair: $91.75Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IRIX1 strengths · Avg: 8.0/10
PEG RatioValuation
0.948/10

Growing faster than its price suggests

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$106.61B9/10

Large-cap with strong market position

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.1%8/10

Strong operational efficiency at 22.1%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

IRIX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$15.51M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-126.4%2/10

ROE of -126.4% — below average capital efficiency

Revenue GrowthGrowth
-0.8%2/10

Revenue declined 0.8%

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.634/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : IRIX

The strongest argument for IRIX centers on PEG Ratio. PEG of 0.94 suggests the stock is reasonably priced for its growth.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : IRIX

The primary concerns for IRIX are EPS Growth, Market Cap, Return on Equity.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

IRIX profiles as a turnaround stock while MDT is a value play — different risk/reward profiles.

IRIX carries more volatility with a beta of 0.64 — expect wider price swings.

MDT is growing revenue faster at 9.9% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (62/100 vs 32/100). IRIX offers better value entry with a 75.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IRIDEX Corporation

HEALTHCARE · MEDICAL DEVICES · USA

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic laser systems, delivery devices, and consumable instrumentation to treat vision-threatening eye diseases in ophthalmology. The company is headquartered in Mountain View, California.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?